GV, Orient Life and Illumina Ventures are in line to exit cell therapy and vaccine developer SQZ Biotechnologies, which has filed for a $75m offering.

SQZ Biotechnologies, a US-based cell therapy developer backed by corporates Alphabet, Orient Life and Illumina, has filed to raise up to $75m in its initial public offering. Founded in 2013, SQZ is working on cell therapy treatments for cancer and infectious diseases based on research at Massachusetts Institute of Technology. Part of the IPO proceeds…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.